EPO in Biological Technology

3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results

...thropoietin ("EPO") products, continued to outpace epo market growth in China. Net revenue from EP...s market leadership position, with 41.1% of epo market share according to fourth quarter 2008 IMS ... sponsored by Amgen. The study shows that among 12 epo products manufactured in Asia, 3SBio's EPIA...

BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism

...his market may come from the proposed bundling structure under which Nephrologists project shifts to subcutaneous dosing, less aggressive treatment of epo hypo-responders, and increased focus on patients' iron status. The commercialization of new ESAs could also alter market dynamics in which Amgen's Ep...

Medgenics Announces Encouraging Preliminary Data For Phase I/II Clinical Trial of EPODURE In Renal Anemia

...ve number needed to provide the intended low daily epo dose of 18-25 IU/kg/day in each subject. The hemog...which is thought to have curtailed the duration of epo delivery in the Company's previous Phase I Clinica...igned to produce and deliver a therapeutic dose of epo steadily for three to six months or more, in Augus...

GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology

...echnology has allowed GenOdyssee to identify in the population a variety of innovative variations on existing key protein drugs such as IFN alphas and epo and to convert such variations into novel drug candidates. The company's lead virology and immunotherapy drug candidates are GEA007.1 and GEA009.2, re...

3SBio Inc. Announces First Quarter 2008 Results

... market as well as from the strong underlying demand in the dialysis market; trends which we believe demonstrate the fundamental health of the Chinese epo market. Net revenues from our TPIAO product increased by 103.8% over the first quarter 2007 to RMB15.4 million (US$2.2 million) due to the continued i...

Japan Patent Office Licenses GeneCards(R) from Xennex, Inc.

...ol for professionals dealing with intellectual property in the life sciences area, including biotech, pharma, and intellectual property law firms. The epo has been using GeneCards very successfully for several years now; with the JPO's licensing of GeneCards, we continue to expand our presence in the int...

Oral PBI-1402 Demonstrates Significant Activity in Chemotherapy-Induced Anemia Phase II Clinical Trial

... active compound being developed to treat different types of anemia, such as CIA. PBI-1402 has a distinct mechanism of action and does not act through epo receptor. ProMetic has recently expanded its clinical program for PBI-1402 into the treatment of anemia in patients with myelodysplastic syndrome ("MD...

Dragon Pharma announces 2007 full year financial results

... per share, compared to an income of $5.4 million or $0.08 per share in 2006. 2007 Full Year Operational Highlights: - Dragon sold its epo business to fully focus on its core antibiotic business that has showed significant growth in the past few years. - Under the favorable market...

Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications

... is a major accomplishment and a step forward," she added. As part of the epo procedure, within a nine-month period following the date of granting of the...ing the patent, amending it or, in certain cases, revoking it. According to epo regulations, the opposed patent is considered and remains granted and enfor...

ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia

... active compound being developed to treat different types of anemia, such as CIA. PBI-1402 has a distinct mechanism of action and does not act through epo receptor. ProMetic has recently expanded its clinical program for PBI-1402 into the treatment of anemia in patients with myelodysplastic syndrome ("MD...

Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents

...tudies conducted outside the label have raised important questions that will be addressed through further research and risk minimization activities. epo Receptors The data remain inconclusive on the hypothesis that the expression of erythropoietin receptors on tumor cells can lead to shortened surviv...

3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2007 Results

...m our flagship injectable recombinant human erythropoietin products, or epo products, marketed under our EPIAO brand, increased 14.7% over the four...ed efficacy and pharmacokinetics studies for NuPIAO, our second- generation epo product, with the toxicology study currently underway. We expect to submit ...

AMT's Lead Product Poised to Address Major Liver Disease

...m NAFLD. At the lowest range of the estimates, 11 percent of these patients develop NASH. Ronald Lorijn, CEO of AMT, said, "We are very pleased that epo granted this important patent to AMT. This substantially widens the potential use of our lead product AMT-011 beyond the current orphan indications to...

European Patent Office Upholds Martek European DHA Food Patent; Scope of Original Claims Narrowed

...stance, Martek cannot predict with certainty any events associated with the epo appeal process, the future actions of Martek's customers or competitors or ...stomers or competitors or the competitive and financial impact of any final epo decision on the value of Martek's intellectual property. These statements s...

The birth of biotech: San Francisco, Boston, Geneva or Chicago?

...he creation of the largest biotech product (called epo or erythropoietin ) and the formation of Amgen, w...Goozner, blood contains more than 200 proteins and epo puts in only a brief appearance. Goldwasser was...of Technology published papers showing that excess epo showed up in urine rather than blood. In 1973, ...

Mirus receives $1.26 million SBIR grant to combat anemia

... EPO, proteins, which help increase the volume of red blood cells. Once the epo enters muscle cells, the expectation is that the body will respond by continually producing epo to maintain a stable level of blood cells. Recipients of the treatment w...

The challenge of financing today's Midwest life science companies

...e optimal. Even stellar biotech company Amgen had to deal away significant rights with its first product to get the money and help it needed to get epo (erythropoietin) to the marketplace. The partner in this case was Johnson & Johnson, which received all the international marketing rights as well as ...

WARF stem cell patent faces long and winding road

...e of human embryos," he said. "This is the position that was adopted by the epo in the Edinburgh University case." The patent office said that the exclu...Office decided that, in such cases, there was no hard-and-fast rule. The epo said "one had to look at all the circumstances and try and adopt a balance ...

FLIPR Calcium 3 Assay Kit Datasheet

...a quenching dye to reduce background fluorescence and improve the signal-to-noise ratio. The patented quench technology (U.S. patent number 6,420,183, epo patent number 0 906 572) is offered to drug discovery and life science researchers exclusively by Molecular Devices, through purchase of FLIPR Assay K...

QBT Fatty Acid Uptake Assay Kit datasheet

...poration. BODIPY is a registered trademark of Molecular Probes, Inc. Quenching technology is covered under U.S. Patent 6,420,183 and epo Patent 0 906 572. back to top ...